Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
Büchner
T
T
Department of Hematology/Oncology, University of Münster, FRG.
Hiddemann
W
W
Blasius
S
S
Koch
P
P
Maschmeyer
G
G
Tirier
C
C
Sodomann
H
H
Kuse
R
R
Thiel
E
E
Ludwig
W D
WD
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005860:Germany, West; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage
D003561:Cytarabine; D003520:Cyclophosphamide; D013866:Thioguanine; D003630:Daunorubicin